The MS Wire - A Column by Ed Tobias

Florida, MS biomarker, Lemtrada, nasal spray Diagnosed with MS at age 32 in 1980, Ed has written the "MS Wire" column for Multiple Sclerosis News Today since August 2016. He presents timely information on MS, blended with personal experiences. Before retiring from full-time work in 2012, Tobias spent more than four decades in broadcast and on-line newsrooms as a manager, reporter, and radio news anchor. He’s won several national broadcast awards. As an MS patient communicator, Ed consults with healthcare and social media companies. He’s the author of “We’re Not Drunk, We Have MS: A tool kit for people living with multiple sclerosis.” Ed and his wife split time between the Washington, D.C. suburbs and Florida’s Gulf Coast.

Online Coronavirus Screening May Not Be Ready for Prime Time

A number of websites are currently offering online coronavirus screening. These aren’t a full-scale test. The online sites read symptoms that you enter and then use artificial intelligence to determine how likely it is that you’re positive for the virus. But there’s a bit of a problem. An investigation by…

Have You Tested Positive for Coronavirus with MS?

What happens if you have MS and you’ve tested positive for COVID-19? How will the disease affect your disease-modifying therapies and your MS? Dr. Barry Singer, (@drbarrysinger), a neurologist who directs The MS Center for Innovations in Care in St. Louis, has posed…

MS News that Caught My Eye Last Week: Coronavirus Updates, MD1003 Trial Fails to Meet Goals, Sativex and Spasticity Relief, NurOwn Trial Site Announced

Second Phase 3 Trial of MedDay’s MD1003 for Progressive MS Fails to Meet Goals This is disappointing news about what scientists had hoped would be another oral disease-modifying therapy for multiple sclerosis. It’s doubly disappointing because MD1003 is aimed at progressive forms of MS and demyelination, and we need…

Guidelines for DMT Use as COVID-19 Spreads

People with multiple sclerosis have unique concerns about the new coronavirus and the COVID-19 disease that it causes. Many of us use disease-modifying therapies (DMTs) that suppress our immune systems and give us an extra element to worry about when we plan our defense against this virus. To help us…

MS News that Caught My Eye Last Week: Remyelination Research in Animal Models, Depression and Neurological Function, Ofatumumab Approval Moves Closer

In this column, I’ll be highlighting some of the research presented at this year’s Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held last week in West Palm Beach, Florida. #ACTRIMS2020 — Remyelination in Adult Animal Brains Possible via Cell Transplant, Study Says You’ll need…

MS Is a Rare Disease? I Think Not

Feb. 29 is Rare Disease Day. It’s a day on which those in the rare disease community attempt to raise awareness about their diseases. I don’t think MS should be included. With about 2.5 million people worldwide in the MS community, I don’t consider it to be rare.

Myeliviz Brings Hope for Faster MS Diagnosis

Myeliviz is the name of a new compound approved for a clinical trial in the U.S. that has the potential to make the process of diagnosing multiple sclerosis faster and tracking the disease progression easier. It does this by providing doctors with a better picture of damaged myelin —…

Smoking and MS: Not a Good Match

Some interesting statistics about people with multiple sclerosis in the U.K. have been released by Public Health England. The numbers are intended to help health commissioners and providers assess “the needs of patients with MS and the provision of health and care services,” according to the government’s website. Primary…

Bladder Problems Keep Many of Us Looking for the Loo

Are you frequently up at night for bathroom trips? When you’re outside, are you always looking for a loo? You’re not alone. A recent study confirms that the vast majority of people with multiple sclerosis are dealing with bladder problems. You probably know the symptoms: They include having…

Stem Cells Versus DMTs: MS Treatments Go Head to Head

People with multiple sclerosis have been waiting for this: A full-scale clinical trial testing the effectiveness of stem cell transplantation as an MS treatment. The trial is being conducted by the U.S. National Institutes of Health, and it’s enrolling people with MS at several centers in the United States and…

MS News that Caught My Eye Last Week: AHSCT Trial Enlisting, Interferon-beta and Pregnancy, Probiotics, Language and Brain Health

New Trial Compares Stem Cell Treatment to Available Therapies for Severe Relapsing MS This is a biggie. The U.S. National Institutes of Health is conducting a head to head study comparing autologous hematopoietic stem cell transplantation (AHSCT) to the high-efficacy, disease-modifying therapies currently being used: Tysabri, Lemtrada, Ocrevus, and…

Who’s Willing to Accept More DMT Risk, You or Your Neuro?

As more high-efficacy disease-modifying therapies (DMTs) are being made available, people with multiple sclerosis have to decide how much risk they’re willing to accept in exchange for the treatment’s potential benefits. It’s a tough decision not made any easier if a patient’s neurologist is unwilling to accept much risk.

Have You Joined the Conversations in Our MS Forums?

About a year and a half ago, Multiple Sclerosis News Today introduced a forums section. It’s a great place to post a question or comment about MS, or to answer someone else’s question. I’m one of the forum moderators, along with John Connor. I get around better than John,…

MS News that Caught My Eye Last Week: Gilenya Generics, MS Pain and Fatigue Toolkit, Profit Drives MS Meds Prices, MS and Sugar Link

FDA Approves Three Generic Versions of Novartis’ Gilenya for Treating Relapsing MS It’s always nice to hear about generics becoming available to replace expensive multiple sclerosis treatments. But I wonder whether these generics will cost less than the brand-name medication. Will their availability help to drive down the price…